麻豆传媒

Dr. Moliterno is a board certified, fellowship trained neurosurgeon specialized in the surgical treatment of all types of primary brain tumors, including gliomas (GBMs, oligodendrogliomas, astrocytomas), meningiomas and acoustic neuromas (vestibular schwannomas), as well as other relatively less common tumor types (medulloblastoma, pineal tumors, intraventricular tumors, epidermoid tumors, etc). She performs the highest volume of brain tumor surgery in the state of Connecticut and routinely cares for patients seeking second or third opinions from afar. Dr. Moliterno has particular expertise in the treatment of complex brain tumors with the safe and effective use of more sophisticated microsurgical techniques, such as functional brain mapping and awake craniotomy for tumors located in highly functioning brain (i.e. speech and motor) areas, as well as those arising along the skull base. Given her skull base surgical specialization, she also routinely performs microvascular decompression for trigeminal neuralgia and hemifacial spasm. Dr. Moliterno is credentialed for performing gamma knife radiosurgery.
Dr. Moliterno serves as the Clinical Director for the Chenevert Family Brain Tumor Center and Chief of Neurosurgical Oncology in the Department of Neurosurgery. She is also the Director of the Multidisciplinary Brain Tumor Board and Precision Brain Tumor Board and the Director for the Neurosurgical Oncology Fellowship Program. She serves as Chair of the Lovemark Foundation Fund at Smilow Cancer Hospital, aimed at providing support for patients with brain tumors.
Dr. Moliterno鈥檚 research interests parallel that of her clinical practice with a bench-to-bedside focus on the clinical implications of the genomics of brain tumors.
She completed her internship and residency training in neurosurgery at Yale New Haven Hospital and clinical fellowship in neurosurgical oncology at the Memorial Sloan-Kettering Cancer Center.

Education & Training
MD
University of Florida College of Medicine (2005)
Fellowship
Memorial Sloan Kettering Cancer Center
Residency
Yale-New Haven Hospital
Internship
Yale-New Haven Hospital

Dr. Omuro is the chief of the Division of Neuro-Oncology and Director of the Yale Brain Tumor Center. He is a graduate and former faculty of the Neuro-Oncology program at Memorial Sloan Kettering Cancer Center in New York. Dr. Omuro is an internationally renowned leader in clinical care and research in the field of brain tumors, having led pivotal research projects and clinical trials to advance the treatment of these difficult cancers. 

Education & Training:
Fellow
Memorial Sloan Kettering Cancer Center (2004)
MD
Sao Paulo School of Medicine (1995)

An international leader in the clinical care of patients with breast cancer, Dr. Krop joined Yale from Dana-Farber Cancer Institute where he was the Associate Chief of the Division of Breast Oncology and an Associate Professor of Medicine at Harvard Medical School. Nationally, he serves as Chief Scientific Officer for the Translational Breast Cancer Research Consortium and the Co-Vice Chair for Correlative Science for the Alliance for Clinical Trials in Oncology. His research efforts have advanced the field through clinical trials that define the next generation of therapies for patients. Dr. Krop serves as a member of the NCI Breast Cancer Steering Committee and the Data Monitoring Committee for ECOG/ACRIN. He also serves on the Data and Safety Monitoring Boards for multiple phase III trials.

Education & Training:
PhD-Johns Hopkins University School of Medicine, Biochemistry, Cellular and Molecular Biology
MD-The Johns Hopkins University School of Medicine, Medicine

Sidi Chen joined the Yale Faculty in 2015 in the Department of Genetics, Systems Biology Institute, and Yale Cancer Center. His research focuses on providing a global understanding of biological systems and development of novel breakthrough therapeutics. Chen developed and applied genome editing and high-throughput screening technologies, precision CRISPR-based in vivo models of cancer, global mapping of functional drivers of cancer oncogenesis and metastasis. He is leading a research group to seek global understandings of the molecular and cellular factors controlling disease progression and immunity. His group continuously invents versatile systems that enable rapid identification of novel targets and development of new modalities of cancer immunotherapy, cell therapy and gene therapy. His goal is to uncover novel insights in cancer and various other immunological diseases and develop next generation therapeutics.
Dr. Chen received a number of national and international awards including the Pershing Square Sohn Prize, DoD Era of Hope Scholar, NIH Director鈥檚 New Innovator Award, Blavatnik Innovator Award, Yale Cancer Center Basic Science Research Prize, AACR NextGen Award for Transformative Cancer Research, Ludwig Foundation Award, Damon Runyon Cancer Research Fellow, Dale Frey Award for Breakthrough Scientists, TMKF Innovative/Translation Cancer Research Award, BCA Exceptional Research Grant Award, MRA Young Investigator Award, V Scholar, Bohmfalk Scholar, Ludwig Family Foundation Award, St. Baldrick鈥檚 Foundation Award, CRI Clinic & Laboratory Integration Program (CLIP), MIT Technology Review Top 35 Innovators (Regional), and Sontag Foundation Distinguished Scientist Award.

Education & Training:
Visiting Postdoc-Broad Institute of MIT and Harvard (2015)
Postdoctoral Fellow-MIT (2015)
PhD-The University of Chicago (2011)
Visiting Student-Stanford University (2009)

Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer, Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.
In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.
Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

Education & Training:
Research Fellow-Dana-Farber Cancer Institute (2002)
Fellow-Harvard Medical School Dermatopathology Training Program (2000)
Chief Resident-Brigham & Women's Hospital (1999)
Resident-Brigham & Women's Hospital (1998)
Research Fellow-University of Wisconsin (1996)
MD-Cornell University Medical College (1994)
PhD-Cornell University Medical College (1993)
BA-Cornell University (1986)

Dr. Mario Sznol is a Professor of Medicine (Medical Oncology). Dr. Sznol, formerly with the National Cancer Institute, has an international reputation in cancer drug development. Dr. Sznol's expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.

Education & Training:
Fellow-Mount Sinai College of Medicine (1987)
Resident-Baylor College of Medicine (1985)
MD-Baylor College of Medicine (1982)
BA-Rice University (1979)

Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis.
Please visit the lab website at:
https://sites.google.com/yale.edu/hklugerlab/home?authuser=3

Education & Training:
Fellow-Yale University School of Medicine (2002)
Resident-University of New Mexico (1995)
MD-Tel Aviv University (1993)

Dr. Kunz joins Yale from Stanford University School of Medicine where she was Director of the Stanford Neuroendocrine Tumor Program, Leader of the Endocrine Oncology Research Group, and Director of the Neuroendocrine Tumor Fellowship. Beyond her record of accomplishment in GI Oncology, Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine tumors (NETs) and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this rare diagnosis.

Education & Training:
Oncology Fellow-Stanford University (2008)
Chief Resident-Stanford University (2005)
Internal Medicine Resident-Stanford University (2004)
MD-Dartmouth Medical School (2001)
BA-Dartmouth College, Biology (1994)

Elena Ratner, M.D. is a Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. Dr. Ratner is a Board Certified Gynecologic oncologist with special interests in chemotherapy targeted drug development, patient quality of life programs and early cancer detection. She is the current co-director of Discovery To Cure, director of Discovery to Cure Early Ovarian Cancer Detection program and a founder and director of Sexuality, Intimacy and Menopause cancer survivorship program. Her expertise is cytoreductive surgery for patients with advanced ovarian cancer, minimally invasive procedures (advanced laparoscopy and robotics) for patients with gynecologic malignancies or complex benign gynecologic conditions, robotic fertility sparing surgery for young patients with cancer. Dr. Ratner's laboratory is working on new targeted drugs for ovarian cancer in order to provide patients with truly personalized care. Her work additionally focuses on reversing chemotherapy resistance in ovarian and uterine cancers. Dr. Ratner is a recipient of multiple clinical and teaching awards, most recently 2015 Yale University Smilow Cancer Center Award for Clinical Excellence.

Education & Training:
MBA-Yale University School of Management (2021)
Fellowship-Yale University School of Medicine (2010)
Residency-Yale-New Haven Hospital (2007)
MD-State University of NY Medical College (2003)
BS-Barnard College - Columbia University, Premedical Studies (1998)

Dr. Lewin completed his undergraduate and medical school education at Harvard followed by residency and breast imaging fellowship at the University of Colorado. He remained in Colorado since then, working successfully in both academic and private practice settings. His research accomplishments include the first clinical trial of digital mammography for screening and the development and first clinical demonstration of dual-energy contrast-enhanced mammography. He has served on many national radiology bodies including ACR鈥檚 ACRIN Working Group on Digital Mammography, its Breast MRI Lexicon Working Group and its Contrast Mammography BI-RADS Group. He is currently the Vice President for the Society of Breast Imaging (SBI) and will be serving as SBI President in 2022.

Education & Training:
MD-Harvard (1990)
MS-University of Rochester, Electrical Engineering (1986)
AB-Harvard, Physics (1982)

Professional Service:
Society of Breast Imaging President (2022-2023)

To Kathleen C. Suozzi, MD, the prevention and reversal of sun damage has become a passion. 鈥淚n my dermatology care and research, I see how sun exposure leads to the development of skin cancers and causes the skin to age prematurely,鈥� she says.
Dr. Suozzi specializes in the treatment of skin cancer with a technique called Mohs surgery. The technique is used to remove cancer cells layer by layer, while preserving normal tissue. She received advanced training in dermatologic surgery at Yale School of Medicine. She is widely published in scientific journals and has presented her research about how skin cancer develops at national conferences including the American Academy of Dermatology, the American Society of Dermatologic Surgery, the Society of Investigative Dermatology and the American College of Mohs Surgery. She鈥檚 committed to alerting people about the dangers of sun exposure. 鈥淧eople accumulate sun damage over a lifetime, starting in childhood. I frequently hear from patients that they were not aware of the risks of sun exposure during their youth,鈥� she says. "But it is never too late to start protecting your skin from UV damage."
In addition to treating skin cancers, Dr. Suozzi uses advanced technologies such as photodynamic therapy, laser treatments and medications to help treat UV-induced damage to the skin. "These technologies can help reverse visible signs of aging and address precancerous changes in the skin,鈥� she says.

Education & Training:
Resident-Yale School of Medicine (2016)
Internship-Memorial Sloan-Kettering Cancer Center (2013)
MD-NYU School Of Medicine (2012)
BS-Duke Univeristy, Biology (2005)

Honors & Recognition:
2022 Rising Star Award-Academic Cosmetic Dermatologists (AACD)

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.” At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says. Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also a member of the Cancer Signaling Networks Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs. One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.” Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma 鈥� a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
鈥淪killed and experienced radiologists are rare for this relatively new technique,鈥� Dr. Sprenkle explains. 鈥淎t Yale, we are fortunate to have some of the world leaders in prostate MRI.鈥�
Dr. Sprenkle is also a pioneer in 鈥渇ocal therapy,鈥� which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects鈥攕uch as erectile dysfunction and incontinence鈥攖hat may follow the removal of the whole prostate.
鈥淓xciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,鈥� Dr. Sprenkle says. 鈥淒eveloping ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.鈥�
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. 鈥淚 want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.鈥�

Education & Training:
Non Degree Program-Yale School of Management, Emerging Leaders Program (2018)
Fellowship-Memorial Sloan Kettering Cancer Center (2011)
Residency-New York Presbyterian Hospital (2009)
Internship-New York Presbyterian Hospital (2005)
MD-Columbia University (2004)
BA-Stanford University, Human Biology (1998)

Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. As a thoracic oncologist she cares for patients with cancers of the chest including lung cancer, mesothelioma and thymoma. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale.  She received her medical degree from Mount Sinai School of Medicine and completed a Masters in Public Health degree from the Harvard School of Public Health. She conducts clinical and translational research on lung cancer with a focus on investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific research interests include EGFR mutation positive lung cancer, immunotherapeutics for lung cancer, and brain metastases. 

Education & Training:
Fellow-Dana-Farber Cancer Institute, Massachusetts General Hospital (2012)
Resident-Massachusetts General Hospital (2009)
MD-Mount Sinai School of Medicine (2006)
MPH-Harvard School of Public Health

Dr. Kapo provides clinical palliative medicine to patients at Smilow Cancer Hospital. In addition, she focuses on developing a research mission in palliative medicine and expanding teaching opportunities for existing Yale faculty, staff, fellows, residents, and medical students. Dr. Kapo was tasked with creating an ACGME certified fellowship in hospice and palliative care.

Education & Training:
Associate Professor-Yale University School of Medicine (2020)
Associate Professor of Clinical Medicine-University of Pennsylvania (2012)
Assistant Professor of Clinical Medicine-University of Pennsylvania (2011)
Instructor-University of Pennsylvania (2005)
Fellowship-University of Pennsylvania (2003)
Fellowship-University of Pennsylvania (2002)
Chief Resident-University of Colorado (2001)
Residency-University of Colorado (2000)
Intern-University of Colorado (1998)
MD-University of Pennsylvania Medical School, MD (1997)
BA-Moravian College, Pre-Medicine (1993)

Terri Parker, MD, is an Assistant Professor of Medicine at the Yale School of Medicine in the section of Hematology. Dr. Parker completed her internal medicine residency at the University of Connecticut followed by a fellowship program in hospice and palliative medicine. She also completed a fellowship in hematology and medical oncology at Yale University School of Medicine.
Dr. Parker serves as the assistant medical director at the Smilow Cancer Hospital Care Center in North Haven that is home to two hematology programs, classical hematology and the multiple myeloma and gammopathies program. She is a member of the protocol review committee (PRC) at the Yale Cancer Center, which is charged with the scientific evaluation of all cancer clinical protocols and amendments proposed at Yale prior to initiation. Dr. Parker currently serves as co-chair of the Multiple Myeloma Committee for ClinicalPath, which presents evidence-based oncology pathways to academic and community practices.
Dr. Parker treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), plasma cell leukemia, smoldering multiple myeloma, and Waldenstrom鈥檚 macroglobulinemia. She has experience with clinical trials focused on novel therapies and drug combinations with a goal of advancing the standard of care for patients with AL amyloidosis, newly diagnosed and relapsed refractory multiple myeloma.


Education & Training:
Fellowship- Yale University School of Medicine (2012)
Fellowship- University of Connecticut Health Center (2009)
Residency- University of Connecticut Health Center (2008)
MD- St. George's University School of Medicine Grenada (2005)
BS- University of Pittsburgh (2001)

Honors & Recognition:

2016 David S. Fischer Teaching Award for Outstanding Faculty Teaching and Mentoring of Fellows in Medical Oncology
2006 Letter of Recognition from Evaluation and Promotions Committee at University of Connecticut

Dr Longman鈥檚 research is primarily focussed on human adaptability. He has developed the use of contemporary sports to study the processes and mechanisms associated with human adaptability and evolution. He currently works with ultra-endurance athletes to enhance understanding of energy and resource allocation during periods of energetic stress.
Danny is an accomplished athlete, having competed nationally in track and field and rowing.
He currently competes in ultra-endurance events and has set numerous British and official World Records in open water swimming and ocean rowing respectively. When not studying or competing, Danny enjoys travelling and cycle touring.

Dr. Alessandro D. Santin, a native of Italy, graduated with honors from the University of Brescia, Italy and received his postgraduate training in Obstetrics & Gynecology at the same University. He served a fellowship in Gynecologic Oncology at the University of California, Irvine and an International Fellowship in the Division of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, Arkansas. In 2000 he became a Clinical Assistant Professor and in 2004 an Associate Professor with Tenure in the same Division. Watch a video with Dr. Alessandro Santin >>
Dr. Santin joined the faculty in the Section of Gynecologic Oncology in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale as Professor as of July 2008. He was the recipient of the American Association young investigator award and the Italian Society of Gynecologic Oncologists award for translational science. Dr. Santin has more that 300 original research and peer-reviewed publications including multiple review articles and book chapters and he has written extensively on various topics, including cancer of the ovary, endometrium and cervix as well as on tumor immunology and immunotherapy.
Dr. Santin's clinical interests include cancer of the ovary, uterus, vagina, cervix and vulva; intraperitoneal chemotherapy, tumor genetics, immunology and immunotherapy; tumor angiogenesis, radiation biology and experimental therapeutics in Gynecologic Oncology. His current research interests include immunotherapy for ovarian, cervical and endometrial carcinomas refractory to standard treatment modalities; development of therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the use of monoclonal antibodies against chemotherapy resistant gynecologic malignancies.
Dr. Santin is a member of the Society of Gynecologic Oncologists, the Gynecologic Oncology Group, The International Gynecologic Oncology Society, the American Medical Association, the American Society of Immunologists, the Italian Society of Gynecologic Oncologists, the American Association for Cancer Research and the American Society of Clinical Oncology

Education & Training:
Fellow- University of Arkansas for Medical Sciences (2000)
Fellow- University of California - Irvine Medical Center (1995)
Resident- University of Brescia School of Medicine (1993)
MD- University of Brescia School of Medicine (1989)

Honors & Recognition:
1999 Genetics Institute Young Investigator Award.	American Association of Cancer Research (AACR)

Dr. Seropian is a Professor of Medicine in the department of Internal Medicine, Section of Hematology, Yale University School of Medicine. He received his medical degree from George Washington University School of Medicine and completed residency and fellowship training at Yale-New Haven Hospital/Yale University School of Medicine in 1996.
Dr. Seropian serves as Interim Director of the Stem Cell Transplant Program, Co-Director, Immune Effector Cell Therapy, and Chairman, Car-T Cell Joint Steering Committee, Yale-New Haven Hospital. Dr. Seropian鈥檚 research interests include methods to improve the outcomes of transplantation through use of novel anti-cancer agents and new methods of treating graft versus host disease

Education & Training:
Resident- Yale-New Haven Hospital (1994)
Intern- Yale-New Haven Hospital (1992)
MD- George Washington University (1991)
BS- Tufts University (1984)

Honors & Recognition:

2016 Yale Cancer Center Award for Clinical Excellence
2014 David S. Fischer Annual Award for Outstanding Teaching and Mentoring of Fellows in Hematology at Yale Cancer Center	
1991 Alpha Omega Alpha Medical Honor Society	AOA
1991 MD with Distinction at George Washington University School of Medicine
1989 Horowitz Award, NBME Part I at George Washington University School of Medicine	

Post-socialist migration, youth migration in Europe, young Europeans in the UK, family migration and ageing, Brexit and migration.
Research includes the geographies and spatialities of children, youth, family and ageing; framed by the overall question: How can people create better lives for themselves and their families through migration and mobility?